Company / EPS (Diluted)
Anika Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.64
FY2025
5-year range
-$5.64 / $1.89
FY2021-FY2025
Trend
-452.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) changed -453% YoY in FY2025, a notable deviation from the 9-year average annual change of -111%.
Based on SEC 10-K filings.
-5.64 in FY2025.
Declined from $0.28 to $-5.64 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 452.9% year-over-year.
- Peak eps (diluted) was recorded in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.64 | -452.9% |
| FY2024 | -$1.02 | -464.3% |
| FY2023 | $0.28 | +116.6% |
| FY2022 | -$1.69 | -189.4% |
| FY2021 | $1.89 | +48.8% |
| FY2020 | $1.27 | -39.8% |
| FY2019 | $2.11 | -1.9% |
| FY2018 | $2.15 | +7.0% |
| FY2017 | $2.01 | -19.9% |
| FY2016 | $2.51 | +80.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026